Clinical trial
ZOSTAVAX(R) Local Registration Trial (V211-019)
NCT00444860 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00444860 |
|---|---|
| Title | ZOSTAVAX(R) Local Registration Trial (V211-019) |
| Official title | A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX(R) in Healthy Adults in Taiwan |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Varicella Virus Infection |
| Intervention type | Biological |
| Interventions | Zoster Vaccine, Live, (Oka-Merck) |
| Enrollment | 150 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Mar 8, 2007 |
| Last update posted | Jun 4, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: